Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 1091-1101

  Bogstedt, Anna ^a,b   Groves, Maria ^c   Tan, Keith ^d   Narwal, Rajesh ^c   McFarlane, Mary ^d   Höglund, Kina ^a,e  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MEDIMMUNE   (United States)

^d MEDIMMUNE LTD   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; amyloid ; biomarkers; cerebrospinal fluid; immunotherapy; plasma; pre clinical

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; HUMAN MONOCLONAL ANTIBODY; MEDI 1814; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ARTICLE; CALIBRATION; CROSS REACTION; DILUTION; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOOD LABORATORY PRACTICE; HEAT TREATMENT; HIGH LIMIT OF QUANTIFICATION; HYDROPHOBICITY; IMMUNOASSAY; LIMIT OF QUANTITATION; LOWER LIMIT OF QUANTITATION; MALE; NONHUMAN; PHARMACODYNAMICS; PRIMATE MODEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; ALZHEIMER DISEASE; ANIMAL; BLOOD; CEREBROSPINAL FLUID; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; MACACA FASCICULARIS; PRECLINICAL STUDY; PROCEDURES; REPRODUCIBILITY; TIME FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOASSAY; MACACA FASCICULARIS; MALE; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84942926893     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142988     Document Type: Article

References (14)

1. Hardy J, Selkoe DJ, 2002 The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297 353 356
2. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K, 2012 A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 96 99
3. Ghosh AK, Brindisi M, Tang J, 2012 Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120 Suppl 1 71 83
4. Pettersson M, Stepan AF, Kauffman GW, Johnson DS, 2013 Novel gamma-secretase modulators for the treatment of Alzheimer's disease: A review focusing on patents from 2010 to 2012. Expert Opin Ther Pat 23 1349 1366
5. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ, 2010 Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330 1774
6. Jindal H, Bhatt B, Sk S, Malik JS, 2014 Alzheimer disease immunotherapeutics: Then and now. Hum Vaccin Immunother 10 2741 2743
7. Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F, 2012 Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 8 135 149
8. Kerchner GA, Boxer AL, 2010 Bapineuzumab. Expert Opin Biol Ther 10 1121 1130
9. Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, Talbot JA, Racke MM, Dean RA, 2013 Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis 34 897 910
10. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, Investigators AAB 2012 Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69 1002 1010
11. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M, 2010 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9 363 372
12. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab, Clinical Trial I 2014 Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 322 333
13. Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, Yeo A, Khan S, Loercher A, Chalker M, Hottenstein C, Zetterberg H, Hilpert J, Mistry P, 2014 Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: A Phase I study. Alzheimers Res Ther 6 19
14. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER, 2012 Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8 261 271